Astrazeneca and Ionis’s discontinuation could herald a nervous time for others in this space.
The developer has now struck two rich deals for the antibiotics space, a field that infrequently sees big sums change hands.
Neither project is an obvious candidate for phase 3, so more mid-stage trials are planned.
When it comes to big pharma’s novel therapies, it is a case of quantity versus quality.
Paradise is now odds-on for US approval – but Medtronic’s rival device is not far behind.
The Pascal valve repair device boasts a pivotal hit and US approval, but can it compete?